(Q35016968)

English

Etoricoxib

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

1 reference

Europe PubMed Central

Etoricoxib. (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Gillian M Keating

3

object named as

Gillian M Keating

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

author name string

Deborah J Cochrane

1

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Blair Jarvis

2

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

publication date

1 January 2002

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

62

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

2637-51; discussion 2652-3

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

https://scigraph.springernature.com/pub.10.2165/00003495-200262180-00006

0 references

Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/12466002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/12466002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/12466002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12466002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12466002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12466002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12466002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273].

1 reference

https://pubmed.ncbi.nlm.nih.gov/12466002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12466002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin

1 reference

https://pubmed.ncbi.nlm.nih.gov/12466002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/12466002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663).

1 reference

https://pubmed.ncbi.nlm.nih.gov/12466002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability--a randomized, placebo-controlled, 3-month trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12466002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12466002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/12466002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/12466002

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-200262180-00006

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35016968&oldid=1973935774"